Ann Arbor, MI21 Active Studies

Heart Attack Clinical Trials in Ann Arbor, MI

Find 21 actively recruiting heart attack clinical trials in Ann Arbor, MI. Connect with local research sites and explore new treatment options.

21
Active Trials
15
Sponsors
5,291
Enrolling

Recruiting Heart Attack Studies in Ann Arbor

RecruitingAnn Arbor, MINCT05164172

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

The main goal of the study is to assess the long-term safety of eptinezumab on children and adolescents ages 6 to 17 with chronic or episodic migraine....

600 participants
H. Lundbeck A/S
View Study Details
RecruitingAnn Arbor, MINCT06615050

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...

572 participants
Incyte Corporation
View Study Details
RecruitingAnn Arbor, MINCT04910685

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants w...

534 participants
Blueprint Medicines Corporation
View Study Details
RecruitingAnn Arbor, MINCT06351631

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bome...

400 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAnn Arbor, MINCT04877522

Asciminib Roll-over Study

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment...

347 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAnn Arbor, MINCT05897320

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants....

315 participants
H. Lundbeck A/S
View Study Details
RecruitingAnn Arbor, MINCT06456346

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

The purpose of this study is to evaluate the efficacy and safety of bomedemstat compared with hydroxyurea in cytoreductive therapy naïve essential thrombocythemia (ET) participants for whom cytoreduct...

300 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAnn Arbor, MINCT05462704

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

Double blind, placebo controlled, multicenter randomized trial in pregnant women in the U.S. (N=300) to test the central hypothesis that IV iron in pregnant women with IDA (Hb\<11 g/dL and ferritin\<3...

300 participants
Women and Infants Hospital of Rhode Island
View Study Details
RecruitingAnn Arbor, MINCT06079879

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate re...

300 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAnn Arbor, MINCT04965675

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine....

285 participants
H. Lundbeck A/S
View Study Details
RecruitingAnn Arbor, MINCT04067336

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

In this trial, ziftomenib, a menin-MLL(KMT2A) inhibitor, will be tested in patients for the first time. The trial includes a Main Study and four sub-studies. In the Main Study (including Phase 1a, Pha...

263 participants
Kura Oncology, Inc.
View Study Details
RecruitingAnn Arbor, MINCT05082519

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...

240 participants
Etan Orgel
View Study Details
RecruitingAnn Arbor, MINCT06616194

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it o...

200 participants
Pfizer
View Study Details
RecruitingAnn Arbor, MINCT06950385

Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

The main goal of this clinical trial is to learn if the drug eRapa works to slow down the progression of disease in patients diagnosed with Familial Adenomatous Polyposis (FAP). Researchers will compa...

168 participants
Rapamycin Holdings Inc.
View Study Details
RecruitingAnn Arbor, MINCT04748601

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age....

132 participants
Upsher-Smith Laboratories
View Study Details
RecruitingAnn Arbor, MINCT06655155

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment...

81 participants
argenx
View Study Details
RecruitingAnn Arbor, MINCT04159103

Open-Label Study of mRNA-3927 in Participants With Propionic Acidemia

This 3-part, Phase 1/2 study is designed to characterize the safety, tolerability, and pharmacological activity (as assessed by biomarker measurements) and to determine the selected dose of mRNA-3927 ...

77 participants
ModernaTX, Inc.
View Study Details
RecruitingAnn Arbor, MINCT05499013

Study to Assess SLN124 in Patients With Polycythemia Vera

This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to ...

65 participants
Silence Therapeutics plc
View Study Details
RecruitingAnn Arbor, MINCT06401356

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionall...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAnn Arbor, MINCT02934568

Ribociclib (LEE011) Rollover Study for Continued Access

This study is to allow continued use of ribociclib (LEE011) as single agent or in combination with other investigational treatments in patients benefitting from treatment in an eligible Novartis-spons...

50 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAnn Arbor, MINCT06328777

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis...

12 participants
Cabaletta Bio
View Study Details

About Heart Attack Clinical Trials in Ann Arbor

A heart attack (myocardial infarction) occurs when blood flow to part of the heart muscle is blocked, usually by a blood clot. It is a medical emergency requiring immediate treatment. Long-term management includes medications, lifestyle changes, and cardiac rehabilitation.

There are currently 21 heart attack clinical trials recruiting participants in Ann Arbor, MI. These studies are seeking a combined 5,291 participants. Research is being sponsored by H. Lundbeck A/S, Incyte Corporation, Blueprint Medicines Corporation and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Heart Attack Clinical Trials in Ann Arbor — FAQ

Are there heart attack clinical trials in Ann Arbor?

Yes, there are 21 heart attack clinical trials currently recruiting in Ann Arbor, MI. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Ann Arbor?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Ann Arbor research site will contact you about next steps.

Are clinical trials in Ann Arbor free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Ann Arbor studies also compensate for your time and travel.

What heart attack treatments are being tested?

The 21 active trials in Ann Arbor are testing new therapies including novel drugs, biologics, and treatment approaches for heart attack.

Data updated March 2, 2026 from ClinicalTrials.gov